1. Apyx One console approved for commercial launch in South Korea. 2. Initial orders expected to start shipping in Q4 2025. 3. South Korea's cosmetic surgery market projected to grow from $1.7B to $3.9B. 4. Renuvion technology targets post-weight-loss skin solutions for patients. 5. Seoul recognized as a global leader in cosmetic surgery and medical tourism.
FAQ
Why Bullish?
The approval and launch in South Korea signify growth potential. Historical examples suggest foreign expansions can boost company valuations.
How important is it?
The South Korean market is lucrative, indicating that success can significantly influence APYX's price.
Why Long Term?
Long-term growth expected as market expands to accommodate advanced cosmetic technologies and increasing demand.
Apyx Medical Corporation Launches Apyx One Console in South Korea
Clearwater, Fla. – December 3, 2025 (GLOBE NEWSWIRE) – Apyx Medical Corporation (Nasdaq: APYX), a front-runner in surgical aesthetics, has announced the approval and upcoming commercial launch of its Apyx One console and single-use handpieces in South Korea. This significant development follows the recent regulatory approval from the Ministry of Food and Drug Safety (MFDS). Initial commercial orders are expected to commence shipping in the fourth quarter of 2025.
Details of the Apyx One Console
The Apyx One console is a multi-functional generator utilizing an advanced 3-in-1 energy system. It allows plastic and cosmetic surgeons to leverage Renuvion technology alongside full monopolar and bipolar energy capabilities. Key features of the Apyx One console include:
- Adaptive and intuitive touch screens
- Procedural presets categorized by body part
- Quantification of energy delivered to specific body areas
- An advanced gas system that measures and monitors gas volume and usage
Market Opportunities for Cosmetic Surgery
President and CEO of Apyx Medical, Charlie Goodwin, expressed enthusiasm over the launch, stating that Seoul is regarded as the cosmetic surgery capital of the world, thriving in medical tourism. The cosmetic surgery market in South Korea is projected to reach $3.9 billion by 2033, up from an estimated $1.7 billion in 2024. Goodwin stated, “As the GLP-1 weight-loss drug market in South Korea grows, we expect more patients will seek solutions for loose skin after significant weight loss, making it an ideal market for our body contouring technology.”
About Apyx Medical Corporation
Apyx Medical Corporation is dedicated to improving lives through innovative surgical aesthetics products, including Renuvion® and the AYON Body Contouring System™. These products facilitate controlled heat delivery to tissues, helping achieve desired surgical outcomes. The AYON system, which integrates several capabilities like fat removal and tissue contraction, offers a comprehensive platform for body contouring procedures while being backed by over 90 clinical documents highlighting its effectiveness.
Forward-Looking Statements
This announcement contains forward-looking statements, including future revenue projections and regulatory approvals. Apyx Medical emphasizes that these statements may differ materially from actual results, influenced by various risks such as regulatory changes, supply chain fluctuations, and market dynamics. The Company plans to adhere to safe harbor protections for forward-looking statements and does not commit to updating these statements in the future.